146 related articles for article (PubMed ID: 11091150)
1. Immunization against human papillomavirus infection and associated neoplasia.
Osen W; Jochmus I; Müller M; Gissmann L
J Clin Virol; 2000 Oct; 19(1-2):75-8. PubMed ID: 11091150
[TBL] [Abstract][Full Text] [Related]
2. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
[TBL] [Abstract][Full Text] [Related]
3. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection.
Schäfer K; Müller M; Faath S; Henn A; Osen W; Zentgraf H; Benner A; Gissmann L; Jochmus I
Int J Cancer; 1999 Jun; 81(6):881-8. PubMed ID: 10362134
[TBL] [Abstract][Full Text] [Related]
4. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity.
Osen W; Peiler T; Ohlschläger P; Caldeira S; Faath S; Michel N; Müller M; Tommasino M; Jochmus I; Gissmann L
Vaccine; 2001 Jul; 19(30):4276-86. PubMed ID: 11457555
[TBL] [Abstract][Full Text] [Related]
5. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
[TBL] [Abstract][Full Text] [Related]
6. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
Peng S; Frazer IH; Fernando GJ; Zhou J
Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
[TBL] [Abstract][Full Text] [Related]
7. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
8. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
[TBL] [Abstract][Full Text] [Related]
10. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
[TBL] [Abstract][Full Text] [Related]
11. Generation and characterization of a preventive and therapeutic HPV DNA vaccine.
Kim D; Gambhira R; Karanam B; Monie A; Hung CF; Roden R; Wu TC
Vaccine; 2008 Jan; 26(3):351-60. PubMed ID: 18096279
[TBL] [Abstract][Full Text] [Related]
12. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
13. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
14. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
15. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine.
Jochmus I; Schäfer K; Faath S; Müller M; Gissmann L
Arch Med Res; 1999; 30(4):269-74. PubMed ID: 10573627
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM
Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326
[TBL] [Abstract][Full Text] [Related]
17. Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells.
Smahel M; Síma P; Ludvíková V; Vonka V
Virology; 2001 Mar; 281(2):231-8. PubMed ID: 11277695
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment.
Cornelison TL
Curr Opin Oncol; 2000 Sep; 12(5):466-73. PubMed ID: 10975555
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor.
Ossevoort MA; Feltkamp MC; van Veen KJ; Melief CJ; Kast WM
J Immunother Emphasis Tumor Immunol; 1995 Aug; 18(2):86-94. PubMed ID: 8574470
[TBL] [Abstract][Full Text] [Related]
20. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
